AKT1 and rheumatoid arthritis: Chen et al. reported that inhibition of PRMT5 by EPZ blocked the production of inflammatory factors and inhibited cell proliferation in fibroblast-like synoviocytes from patients with rheumatoid arthritis through the NF-κB and AKT pathways, suggesting that PRMT5 may be a promising target for the prevention of synovial inflammation and destruction [44].